Filing Flows › Arcutis Biotherapeutics (ARQT) › Capital expenditures
Arcutis Biotherapeutics (ARQT) capital expenditures by quarter
Arcutis Biotherapeutics' capital expenditures were $97K in Q3 2026 (third quarter 2026), -39% from Q2 2026. Over the last 3 quarters it ranged from $78K (Q2 2025) to $158K (Q2 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $97K | -39% | — |
| Q2 2026 | $158K | +103% | +103% |
| Q2 2025 | $78K | — | — |
Q3 2026 at a glance
Arcutis Biotherapeutics, Q3 2026: revenue $144M (+45% year over year), operating margin 6.6%, net earnings $8.8M, operating cash flow $18.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Arcutis Biotherapeutics' capital expenditures?
Arcutis Biotherapeutics' capital expenditures were $97K in Q3 2026 (third quarter 2026), -39% from Q2 2026.
How has Arcutis Biotherapeutics' capital expenditures changed?
Over the last 3 quarters it ranged from $78K (Q2 2025) to $158K (Q2 2026).
Q3 2026 results → · How Arcutis Biotherapeutics makes money →